No Data
Here's Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN)
Is BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Recent Price Movement Underpinned By Its Weak Fundamentals?
Peering Into Biomarin Pharmaceutical's Recent Short Interest
CAMP4 Analyst Highlights Rare Disease Platform Potential
Wedbush Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $94
Express News | Biomarin Pharmaceutical Inc : Wedbush Assumes Coverage With Outperform Rating; Target Price $94
No Data
No Data